Long-term outcome following selective serotonin reuptake inhibitor induced neonatal abstinence syndrome

J Perinatol. 2011 Sep;31(9):615-20. doi: 10.1038/jp.2010.211. Epub 2011 Feb 10.

Abstract

Objective: To assess the long-term neurodevelopment of children exposed in utero to selective serotonin reuptake inhibitors (SSRIs) that developed a neonatal abstinence syndrome (NAS).

Study design: Neurodevelopmental evaluation was performed at the age of 2 to 6 years. Children who developed NAS were compared with those who did not using univariate and logistic regression analyses.

Result: Thirty children with NAS and 52 without NAS participated in the study. Both groups were similar in mean cognitive ability (106.9±14.0 vs 100.5±14.6, P=0.12) and developmental scores (98.9±11.4 vs 95.7±9.9, P=0.21). However, there was a trend towards small head circumference in the NAS group (20 vs 6%, P=0.068). NAS was associated with an increased risk of social-behavior abnormalities (odds ratio (OR) 3.03, 95% confidence interval (CI) 1.07 to 8.60, P=0.04) and advanced maternal age (OR 1.12, 95% CI 1.00 to 1.25, P=0.04).

Conclusion: Infants who developed NAS had normal cognitive ability, but were at an increased risk for social-behavioral abnormalities. Follow-up evaluation of symptomatic neonates should be considered.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Child
  • Child Development / drug effects
  • Child, Preschool
  • Female
  • Humans
  • Infant, Newborn
  • Male
  • Mental Disorders / chemically induced
  • Mental Disorders / diagnosis
  • Neonatal Abstinence Syndrome / etiology
  • Neonatal Abstinence Syndrome / psychology*
  • Neuropsychological Tests
  • Pregnancy
  • Prenatal Exposure Delayed Effects*
  • Prospective Studies
  • Selective Serotonin Reuptake Inhibitors / adverse effects*
  • Selective Serotonin Reuptake Inhibitors / pharmacology
  • Treatment Outcome

Substances

  • Serotonin Uptake Inhibitors